A federal grand jury indicted Alzheimer's researcher Hoau-Yan Wang for falsifying data to secure $16 million for an Alzheimer's drug. Doubts surround Cassava Sciences' Simufilam, on which Wang's research was based.
An internal investigation revealed 'egregious misconduct in data management' by Wang, casting doubt on the integrity of the research. Wang's failure to provide original data raised suspicions.
Collection
[
|
...
]